Investment Rating - The report does not provide a specific investment rating for the industry [3] Core Insights - The industry of Poria cocos health food, which primarily uses Poria as a raw material, has a broad development prospect due to its historical application and increasing consumer health awareness [3][12] - The market size of Poria cocos health food has grown from 5.321 billion RMB in 2019 to 5.923 billion RMB in 2023, with a compound annual growth rate (CAGR) of 2.72%. It is expected to reach 7.548 billion RMB by 2028, with a CAGR of 5.00% [29][32] Industry Definition - Poria cocos health food refers to health products made primarily from Poria, a traditional medicinal fungus known for its diuretic and calming effects [4][10] Industry Classification - The Poria cocos health food industry can be classified based on dosage forms, including capsules, oral liquids, tablets, and other forms [6][7] Industry Characteristics - The industry has a long application history and a stable consumer base, with strict regulations ensuring safety and effectiveness [10][13] - Government policies are supportive, encouraging the development of traditional Chinese medicine and facilitating the entry of Poria into the health food market [14] Development History - The industry has undergone two main phases: the initiation phase (1996-2015) where regulatory frameworks were established, and the rapid development phase (2016-2024) marked by simplified market entry processes and increased public awareness [15][17] Supply Chain Analysis - The supply chain includes stable raw material supply, technological innovation in processing, and market distribution [18] - The main production areas for Poria are in Hunan, Hubei, and Anhui, with Hunan accounting for approximately 70% of the national supply [20] Market Trends - The demand for Poria cocos health food is driven by rising health consciousness among consumers, with a notable preference for products claiming to enhance immunity and alleviate fatigue [26][28] - The market is characterized by a low entry barrier and significant product homogeneity, leading to a prevalent private label production model [42][43] Competitive Landscape - The industry is fragmented with no dominant players, featuring a mix of listed and non-listed companies [42] - Major companies include Beijing Tongrentang, Renhe Pharmaceutical, and Huazhong Pharmaceutical, with varying market shares and growth rates [46][47]
茯苓类保健食品：传统大宗药材融入保健食品，发展前景广阔 头豹词条报告系列
Tou Bao Yan Jiu Yuan·2024-11-20 13:41